Navigation Links
Somanetics Receives 510(k) Clearance From the FDA to Expand Features on Its Vital Sync Monitor

TROY, Mich., May 24 /PRNewswire-FirstCall/ -- Somanetics Corporation (Nasdaq: SMTS) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand features on its Vital Sync™ bedside monitor and research data aggregation system.  The clearance allows for interface with a broader range of bedside devices, display of derived parameters of calculated clinical indices, and an automated events trigger to alert clinicians when patient parameters fall outside desired thresholds.

"We believe this new 510(k) supports our goal of providing monitoring technologies that help critical care clinicians simplify and manage the wealth of patient data involved in assessing and treating patients," said Bruce Barrett, Somanetics' president and chief executive officer.  "Connectivity and display of additional vital patient parameters provides clinicians with 'dash-board' patient data to help clinicians' decision making and delivery of bedside care."

Somanetics' Vital Sync system provides the clinician with a view of patient data at the point of care to help medical professionals detect deteriorating patient condition early.  The Vital Sync system allows the clinician to select specific patient data from an array of bedside devices and view the data on a single, time-synced display at the bedside.  This focuses the clinician on relevant and interrelated patient data to enhance treatment decisions and improve patient care.

"Expanded compatibility with body cooling and perfusion equipment provides a more comprehensive device package for our neonatal and pediatric intensive care customers where hypothermic and ECMO treatment are used," adds Henry Szymanski, Somanetics' senior marketing manager.  "In addition, the derived parameters and automated events features are expected to help clinicians transform individual patient metrics and events into more meaningful and actionable information."

About Somanetics

Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS® Cerebral/Somatic Oximeter.  The INVOS System is the only commercially-available cerebral/somatic oximeter with labeling for improved outcomes after surgery in patients above 2.5 kg.  The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with a 12-year market track record, more than 750 clinical references and implementation at approximately 800 U.S. hospitals.  Somanetics also develops, manufactures and markets the Vital Sync™ System, a device that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage.  Somanetics supports its customers through a direct U.S. sales force and clinical education team.  Covidien markets INVOS System products in Europe, Canada, the Middle East and South Africa and Edwards Lifesciences represents INVOS System products in Japan.  For more information visit

SOURCE Somanetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
2. Somanetics Corporation To Release First Quarter 2010 Financial Results and Host Conference Call March 17, 2010
3. Somanetics Corporation to Release Fourth Quarter and Fiscal 2009 Financial Results and Host Conference Call January 21, 2010
4. Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University
5. LensAR Laser System(TM) Receives FDA Clearance for Use in Cataract Surgery
6. China Sky One Medicals CEO Receives Award For "Leadership Excellence In Innovation"
7. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
8. DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
9. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
10. VetCentric Receives Vet-VIPPS Certification from NABP
11. Mylan Receives Approval for Generic Version of Zyban(R)
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):